In a proof-of-concept randomised sequential trial in treatment‑resistant depression, responders to six ketamine infusions were randomised to 14 weeks of CBT versus treatment‑as‑usual and CBT showed a significant group-by-time advantage on self-report depressive symptoms (QIDS; moderate-to-large Cohen d ≈ 0.71), while the primary clinician-rated outcome (MADRS) showed a non-significant moderate effect (d = 0.65). A subset analysis also found improved accuracy on an emotional N‑back task among ketamine responders.
- Published
- Journal
- Psychotherapy and Psychosomatics
- Authors
- Wilkinson, S. T., Taeho, G., Rhee, Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., Sanacora, G.